HCW Biologics Files 8-K/A Amendment

TL;DR

HCW Biologics filed an amendment to its 8-K, updating financial and operational info.

AI Summary

HCW Biologics Inc. filed an 8-K/A on August 23, 2024, to amend a previous filing concerning the results of operations and financial condition as of August 14, 2024. The amendment pertains to financial statements and exhibits, as well as Regulation FD disclosures.

Why It Matters

This filing is an amendment to a previous report, indicating that HCW Biologics is correcting or adding information related to its financial condition and operations.

Risk Assessment

Risk Level: low — This is a routine amendment to a previous filing, not indicating new material events or significant financial changes.

Key Players & Entities

• HCW Biologics Inc. (company) — Registrant
• August 14, 2024 (date) — Earliest event reported
• August 23, 2024 (date) — Filing date
• 2929 N. Commerce Parkway, Miramar, Florida 33025 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share HCWB The Nasdaq Stock Mar

Filing Documents

• hcwb-20240814.htm (8-K/A) — 47KB
• hcwb-ex99_1.htm (EX-99.1) — 141KB
• img90053791_0.jpg (GRAPHIC) — 46KB
• 0000950170-24-100221.txt ( ) — 387KB
• hcwb-20240814.xsd (EX-101.SCH) — 28KB
• hcwb-20240814_htm.xml (XML) — 6KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On August 23, 2024, HCW Biologics Inc. issued a press release reporting a correction to a press release previously issued on August 14, 2024, announcing its financial results for the quarter ended June 30, 2024, which was included as Exhibit 99.1 to the Original Form 8-K. The full text of the press release reporting the correction to the press release issued on August 14, 2024 is furnished as Exhibit 99.1 to this Amendment and is incorporated herein by reference.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure The information set forth in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated August 14, 2024 (corrected). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. HCW BIOLOGICS INC. Date: August 23, 2024 By: /s/ Hing C. Wong Hing C. Wong Founder and Chief Executive Officer

View Full Filing

View this 8-K/A filing on SEC EDGAR